Amcor makes a move for Alcan Packaging

Article

Pharmaceutical Technology Europe PTE

Amcor (Australia) has made an offer of $2025 million for parts of Alcan Packaging (France), including the company's global pharmaceuticals division.

Amcor (Australia) has made an offer of $2025 million for parts of Alcan Packaging (France), including the company's global pharmaceuticals division. Alcan is currently a part of Rio Tinto, a mining group headquartered in the UK. Rio Tinto has acknowledged the offer and will respond following consultation with European works councils; however, in a statement the company has already said: "We believe Amcor's offer is in the interests of all stakeholders. These businesses would be acquired by a leading player in the global packaging sector that is well placed to enable ongoing success."

Amcor is also confident that the acquisition is a recipe for success. A statement from the company explained that the acquisition will allow it to provide broader offerings and enhanced customer service. "Critically, beyond the hard assets, the combined company will draw on the best people from both organizations to drive these improvements," Ken MacKenzie, Amcor's Managing Director and CEO, added in a statement from Amcor.

Amcor has offered to acquire four divisions of Alcan: global pharmaceuticals, food Europe, Food Asia and global tobacco. The divisions will provide Amcor with 80 plants across 24 countries, as well as 14000 employees, and are expected to add approximately $4.1 billion in sales.

In a separate statement issued by Amcor's healthcare division, Bob Biasi, Vice President Technology at Amcor Flexibles Healthcare, added: "Alcan Packaging has a strong history of creating high-performance products, as does Amcor. The combined business will provide customers with better solutions faster."

www.amcor.comwww.alcanpackaging.comwww.riotinto.com

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content